Loading…
Loading…
ABT.SW (Abbott Laboratories) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABT.SW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABT.SW and 80,000+ other tickers.
See exactly how ABT.SW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABT.SW and 80,000+ other tickers.
Abbott Laboratories, a global healthcare company operating through its various subsidiaries, is committed to the research, development, production, and sale of a diverse portfolio of health-related products worldwide. Its operations are structured into four main divisions: The Established Pharmaceutical Products segment offers generic medications for a broad spectrum of conditions. These include treatments for pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis, depressive symptoms, gynecological disorders, and hormone replacement therapy. It also provides…
No recent news available.